Rubius Therapeutics, Inc.
NASDAQ: RUBY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurence A. Turka
- Employees
- 6
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Website
- https://www.rubiustx.com
Loading RUBY…
Loading profile data…Frequently asked questions about RUBY
What does Rubius Therapeutics, Inc. (RUBY) do?
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressi...
Where does RUBY trade?
Rubius Therapeutics, Inc. (RUBY) trades on the NASDAQ Global Select.
What sector is RUBY in?
Rubius Therapeutics, Inc. (RUBY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rubius Therapeutics, Inc.?
Laurence A. Turka is the chief executive officer of Rubius Therapeutics, Inc. (RUBY).
Where is Rubius Therapeutics, Inc. headquartered?
Rubius Therapeutics, Inc. is headquartered in United States.
Does RUBY pay a dividend?
Rubius Therapeutics, Inc. (RUBY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RUBY go public?
Rubius Therapeutics, Inc. (RUBY) completed its initial public offering in 2018.